Correlation of miRNA and VEGF expression with the outcome of early-onset severe preeclampsia in patients receiving expectant treatment

Li Han; Yin Zhao; Zhishan Jin; Yanhui Li; Li Zou

Correlation of miRNA and VEGF expression with the outcome of early-onset severe preeclampsia in patients receiving expectant treatment

Int J Clin Exp Pathol. 2018 Apr 1;11(4):2137-2141. eCollection 2018.

Authors

Li Han¹, Yin Zhao¹, Zhishan Jin¹, Yanhui Li¹, Li Zou¹

Affiliation

¹ Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, China.

PMID: 31938323
PMCID: PMC6958206

Abstract

The present study was planned to explore the relationship between miRNA and VEGF expression in serum as well as placenta tissue with the outcome of early-onset severe preeclampsia (EOSP) in patients receiving expectant treatment. Sixty EOSP patients who had expectant treatment indications were divided into the success group (n = 46) and the failure group (n = 14) according to the pregnancy outcomes. miR-210 and miR-155 expression levels were studied in serum, ante partum, and in placenta tissue. The vascular endothelial growth factor (VEGF) and soluble VEGF receptor 1 (sFlt-1) expression levels were also explored. miR-210 and miR-155 expression levels in serum and placenta tissue before treatment, ante partum, and after accouchement of the success group were significantly lower than those of the failure group. Further, VEGF expression levels in serum and placenta tissue before treatment, ante partum, and after accouchement of the success group were significantly higher than those of the failure group. However, sFlt-1 expression levels in the success group showed a decrease in comparison to the failure group. The increase of miR-210, miR-155 levels, sFlt-1 levels, and the decrease of VEGF levels in EOSP patients might be correlated with the failure of expectant treatment.

Keywords: Early-onset severe preeclampsia (EOSP); expectant treatment; miRNAs; soluble VEGF receptor 1 (sFlt-1); vascular endothelial growth factor (VEGF).